165 related articles for article (PubMed ID: 32801164)
1. Diffuse Intrinsic Pontine Glioma Cells Are Vulnerable to Mitotic Abnormalities Associated with BMI-1 Modulation.
Senthil Kumar S; Sengupta S; Zhu X; Mishra DK; Phoenix T; Dyer L; Fuller C; Stevenson CB; DeWire M; Fouladi M; Drissi R
Mol Cancer Res; 2020 Nov; 18(11):1711-1723. PubMed ID: 32801164
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of mutant PPM1D enhances DNA damage response and growth suppressive effects of ionizing radiation in diffuse intrinsic pontine glioma.
Akamandisa MP; Nie K; Nahta R; Hambardzumyan D; Castellino RC
Neuro Oncol; 2019 Jun; 21(6):786-799. PubMed ID: 30852603
[TBL] [Abstract][Full Text] [Related]
3. Combined Therapy of AXL and HDAC Inhibition Reverses Mesenchymal Transition in Diffuse Intrinsic Pontine Glioma.
Meel MH; de Gooijer MC; Metselaar DS; Sewing ACP; Zwaan K; Waranecki P; Breur M; Buil LCM; Lagerweij T; Wedekind LE; Twisk JWR; Koster J; Hashizume R; Raabe EH; Montero Carcaboso Á; Bugiani M; Phoenix TN; van Tellingen O; van Vuurden DG; Kaspers GJL; Hulleman E
Clin Cancer Res; 2020 Jul; 26(13):3319-3332. PubMed ID: 32165429
[TBL] [Abstract][Full Text] [Related]
4. Radiosensitization by Histone H3 Demethylase Inhibition in Diffuse Intrinsic Pontine Glioma.
Katagi H; Louis N; Unruh D; Sasaki T; He X; Zhang A; Ma Q; Piunti A; Shimazu Y; Lamano JB; Carcaboso AM; Tian X; Seluanov A; Gorbunova V; Laurie KL; Kondo A; Wadhwani NR; Lulla R; Goldman S; Venneti S; Becher OJ; Zou L; Shilatifard A; Hashizume R
Clin Cancer Res; 2019 Sep; 25(18):5572-5583. PubMed ID: 31227500
[TBL] [Abstract][Full Text] [Related]
5. BMI-1 is a potential therapeutic target in diffuse intrinsic pontine glioma.
Kumar SS; Sengupta S; Lee K; Hura N; Fuller C; DeWire M; Stevenson CB; Fouladi M; Drissi R
Oncotarget; 2017 Sep; 8(38):62962-62975. PubMed ID: 28968963
[TBL] [Abstract][Full Text] [Related]
6. Transcriptomic Analysis of Diffuse Intrinsic Pontine Glioma (DIPG) Identifies a Targetable ALDH-Positive Subset of Highly Tumorigenic Cancer Stem-like Cells.
Surowiec RK; Ferris SF; Apfelbaum A; Espinoza C; Mehta RK; Monchamp K; Sirihorachai VR; Bedi K; Ljungman M; Galban S
Mol Cancer Res; 2021 Feb; 19(2):223-239. PubMed ID: 33106374
[TBL] [Abstract][Full Text] [Related]
7. TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist.
Xu C; Liu H; Pirozzi CJ; Chen LH; Greer PK; Diplas BH; Zhang L; Waitkus MS; He Y; Yan H
Acta Neuropathol Commun; 2021 Nov; 9(1):178. PubMed ID: 34732238
[TBL] [Abstract][Full Text] [Related]
8. Reversal of cancer gene expression identifies repurposed drugs for diffuse intrinsic pontine glioma.
Zhao G; Newbury P; Ishi Y; Chekalin E; Zeng B; Glicksberg BS; Wen A; Paithankar S; Sasaki T; Suri A; Nazarian J; Pacold ME; Brat DJ; Nicolaides T; Chen B; Hashizume R
Acta Neuropathol Commun; 2022 Oct; 10(1):150. PubMed ID: 36274161
[TBL] [Abstract][Full Text] [Related]
9. H3.3 K27M depletion increases differentiation and extends latency of diffuse intrinsic pontine glioma growth in vivo.
Silveira AB; Kasper LH; Fan Y; Jin H; Wu G; Shaw TI; Zhu X; Larson JD; Easton J; Shao Y; Yergeau DA; Rosencrance C; Boggs K; Rusch MC; Ding L; Zhang J; Finkelstein D; Noyes RM; Russell BL; Xu B; Broniscer A; Wetmore C; Pounds SB; Ellison DW; Zhang J; Baker SJ
Acta Neuropathol; 2019 Apr; 137(4):637-655. PubMed ID: 30770999
[TBL] [Abstract][Full Text] [Related]
10. Identification of Novel RAS Signaling Therapeutic Vulnerabilities in Diffuse Intrinsic Pontine Gliomas.
Koncar RF; Dey BR; Stanton AJ; Agrawal N; Wassell ML; McCarl LH; Locke AL; Sanders L; Morozova-Vaske O; Myers MI; Hamilton RL; Carcaboso AM; Kohanbash G; Hu B; Amankulor NM; Felker J; Kambhampati M; Nazarian J; Becher OJ; James CD; Hashizume R; Broniscer A; Pollack IF; Agnihotri S
Cancer Res; 2019 Aug; 79(16):4026-4041. PubMed ID: 31201162
[TBL] [Abstract][Full Text] [Related]
11. Poly-ADP-Ribose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma and Pediatric High-Grade Astrocytoma.
Chornenkyy Y; Agnihotri S; Yu M; Buczkowicz P; Rakopoulos P; Golbourn B; Garzia L; Siddaway R; Leung S; Rutka JT; Taylor MD; Dirks PB; Hawkins C
Mol Cancer Ther; 2015 Nov; 14(11):2560-8. PubMed ID: 26351319
[TBL] [Abstract][Full Text] [Related]
12. Chaetocin-mediated SUV39H1 inhibition targets stemness and oncogenic networks of diffuse midline gliomas and synergizes with ONC201.
Xin DE; Liao Y; Rao R; Ogurek S; Sengupta S; Xin M; Bayat AE; Seibel WL; Graham RT; Koschmann C; Lu QR
Neuro Oncol; 2024 Apr; 26(4):735-748. PubMed ID: 38011799
[TBL] [Abstract][Full Text] [Related]
13. Dual targeting of the epigenome via FACT complex and histone deacetylase is a potent treatment strategy for DIPG.
Ehteda A; Simon S; Franshaw L; Giorgi FM; Liu J; Joshi S; Rouaen JRC; Pang CNI; Pandher R; Mayoh C; Tang Y; Khan A; Ung C; Tolhurst O; Kankean A; Hayden E; Lehmann R; Shen S; Gopalakrishnan A; Trebilcock P; Gurova K; Gudkov AV; Norris MD; Haber M; Vittorio O; Tsoli M; Ziegler DS
Cell Rep; 2021 Apr; 35(2):108994. PubMed ID: 33852836
[TBL] [Abstract][Full Text] [Related]
14. Targeting Mutant PPM1D Sensitizes Diffuse Intrinsic Pontine Glioma Cells to the PARP Inhibitor Olaparib.
Wang Z; Xu C; Diplas BH; Moure CJ; Chen CJ; Chen LH; Du C; Zhu H; Greer PK; Zhang L; He Y; Waitkus MS; Yan H
Mol Cancer Res; 2020 Jul; 18(7):968-980. PubMed ID: 32229503
[TBL] [Abstract][Full Text] [Related]
15. Mesenchymal Stem Cells Successfully Deliver Oncolytic Virotherapy to Diffuse Intrinsic Pontine Glioma.
Chastkofsky MI; Pituch KC; Katagi H; Zannikou M; Ilut L; Xiao T; Han Y; Sonabend AM; Curiel DT; Bonner ER; Nazarian J; Horbinski CM; James CD; Saratsis AM; Hashizume R; Lesniak MS; Balyasnikova IV
Clin Cancer Res; 2021 Mar; 27(6):1766-1777. PubMed ID: 33272983
[TBL] [Abstract][Full Text] [Related]
16. A kinome-wide shRNA screen uncovers vaccinia-related kinase 3 (VRK3) as an essential gene for diffuse intrinsic pontine glioma survival.
Silva-Evangelista C; Barret E; Ménez V; Merlevede J; Kergrohen T; Saccasyn A; Oberlin E; Puget S; Beccaria K; Grill J; Castel D; Debily MA
Oncogene; 2019 Sep; 38(38):6479-6490. PubMed ID: 31324890
[TBL] [Abstract][Full Text] [Related]
17. Senescence Induced by BMI1 Inhibition Is a Therapeutic Vulnerability in H3K27M-Mutant DIPG.
Balakrishnan I; Danis E; Pierce A; Madhavan K; Wang D; Dahl N; Sanford B; Birks DK; Davidson N; Metselaar DS; Meel MH; Lemma R; Donson A; Vijmasi T; Katagi H; Sola I; Fosmire S; Alimova I; Steiner J; Gilani A; Hulleman E; Serkova NJ; Hashizume R; Hawkins C; Carcaboso AM; Gupta N; Monje M; Jabado N; Jones K; Foreman N; Green A; Vibhakar R; Venkataraman S
Cell Rep; 2020 Oct; 33(3):108286. PubMed ID: 33086074
[TBL] [Abstract][Full Text] [Related]
18. MELK Inhibition in Diffuse Intrinsic Pontine Glioma.
Meel MH; de Gooijer MC; Guillén Navarro M; Waranecki P; Breur M; Buil LCM; Wedekind LE; Twisk JWR; Koster J; Hashizume R; Raabe EH; Montero Carcaboso A; Bugiani M; van Tellingen O; van Vuurden DG; Kaspers GJL; Hulleman E
Clin Cancer Res; 2018 Nov; 24(22):5645-5657. PubMed ID: 30061363
[No Abstract] [Full Text] [Related]
19. TP53 Pathway Alterations Drive Radioresistance in Diffuse Intrinsic Pontine Gliomas (DIPG).
Werbrouck C; Evangelista CCS; Lobón-Iglesias MJ; Barret E; Le Teuff G; Merlevede J; Brusini R; Kergrohen T; Mondini M; Bolle S; Varlet P; Beccaria K; Boddaert N; Puget S; Grill J; Debily MA; Castel D
Clin Cancer Res; 2019 Nov; 25(22):6788-6800. PubMed ID: 31481512
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic targeting of transcriptional elongation in diffuse intrinsic pontine glioma.
Katagi H; Takata N; Aoi Y; Zhang Y; Rendleman EJ; Blyth GT; Eckerdt FD; Tomita Y; Sasaki T; Saratsis AM; Kondo A; Goldman S; Becher OJ; Smith E; Zou L; Shilatifard A; Hashizume R
Neuro Oncol; 2021 Aug; 23(8):1348-1359. PubMed ID: 33471107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
